Bevacizumab in non-small-cell lung cancer: a review.

abstract：:Cancer-related anorexia/cachexia syndrome is a complex phenomenon in which metabolic abnormalities, proinflammatory cytokines produced by the host immune system, circulating tumor-derived catabolic factors, decreased food intake and probably additional unknown factors all play different roles. This review examines the...

journal_title：Expert review of anticancer therapy

authors： Mantovani G,Macciò A,Madeddu C,Massa E

更新日期：2003-06-01 00:00:00

abstract：:Introduction: It has long been recognized that tumors are composed of a mosaic of cells and numerous methods have been developed to detect tumor heterogeneity, including in situ hybridization, multi-regional sampling, cytological assays, and whole genome and single cell sequencing. Using these methods, heterogeneity h...

journal_title：Expert review of anticancer therapy

authors： Turnquist C,Watson RA,Protheroe A,Verrill C,Sivakumar S

更新日期：2019-10-01 00:00:00

abstract：:A number of important studies were presented at the CNS tumors section of the 2010 American Society of Oncology (ASCO) Annual Meeting. There was particular interest in a Phase II study showing that the mTOR inhibitor everolimus had significant activity in tuberous patients with subependymal giant cell astrocytomas. Tw...

journal_title：Expert review of anticancer therapy

authors： Wen PY

更新日期：2010-09-01 00:00:00

abstract：BACKGROUND:Chemotherapy-induced toxic liver injury is a relevant issue in the clinical management of patients affected with metastatic colorectal cancer (mCRC). This retrospective study evaluated patterns of liver toxicity in patients treated with FOLinic acid, Fluorouracil, IRInotecan (FOLFIRI)-based regimens. METHOD...

journal_title：Expert review of anticancer therapy

authors： Vincenzi B,Imperatori M,Picardi A,Vespasiani Gentilucci U,Gallo P,Fausti V,Spalato Ceruso M,Santini D,Tonini G

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Despite a variety of therapies for advanced metastatic colorectal cancer being available, the outcomes in this malignancy remain suboptimal. Immunotherapy has been slow to impact the management of this patient group. Checkpoint inhibitors, such as nivolumab, have had disappointing results when used broadly...

journal_title：Expert review of anticancer therapy

authors： Smith KM,Desai J

更新日期：2018-07-01 00:00:00

abstract：:Knowledge of the prognostic role of biomarkers in colorectal cancer is limited and the routine determination for clinical practice is not warranted. However, for some of these markers, data are promising enough for further evaluation. This review addresses a comprehensive analysis of prognostic biomarkers in colorecta...

journal_title：Expert review of anticancer therapy

authors： Graziano F,Catalano V,Baldelli AM,Cascinu S

更新日期：2001-08-01 00:00:00

abstract：:Breast cancer represents a major health problem, with more than a million new cases and 370,000 deaths worldwide yearly. Options and understanding of how to use cytotoxic chemotherapy in both advanced and early stage breast cancer have made substantial progress in the past 10 years, with numerous landmark studies iden...

journal_title：Expert review of anticancer therapy

authors： Hussain SA,Palmer DH,Stevens A,Spooner D,Poole CJ,Rea DW

更新日期：2005-12-01 00:00:00

abstract：:Nonseminomatous germ cell tumors of the testicle are highly treatable and curable. The evolution of cancer control for this disease has demonstrated an effective integration of medical and surgical approaches over the last 30 years. Current emphasis in the therapy of nonseminomatous germ cell tumors focuses on minimiz...

journal_title：Expert review of anticancer therapy

authors： Yoon GH,Stein JP,Skinner DG

更新日期：2005-02-01 00:00:00

abstract：:The advent of granulocyte colony-stimulating factor, in particular filgrastim, in clinical use more than 10 years ago made a significant impact on the management of neutropenia and its complications. More recently, the application of pegylation technology has created a second-generation molecule, pegfilgrastim, with s...

journal_title：Expert review of anticancer therapy

authors： Ng R,Green MD

更新日期：2005-08-01 00:00:00

abstract：:Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel-based chemotherapy. Two agents (cabazitaxel and abiraterone) are already accessible to prescribers, having shown survival be...

journal_title：Expert review of anticancer therapy

authors： Birtle A

更新日期：2013-01-01 00:00:00

abstract：:Today dermoscopy is standard-of-care in the diagnosis and management of patients with benign and malignant skin tumors because it increases the diagnostic accuracy of skin lesions compared to the naked-eye examination up to 25%. Despite its role in the routine dermato-oncology, it increasingly gained interest as a bri...

journal_title：Expert review of anticancer therapy

authors： Woltsche N,Schwab C,Deinlein T,Hofmann-Wellenhof R,Zalaudek I

更新日期：2016-05-01 00:00:00

abstract：:Atypical hyperplasia and lobular carcinoma in situ are rare proliferative breast lesions, growing inside ducts and terminal ducto-lobular units. They represent a marker of increased risk for breast cancer and a non-obligate precursor of malignancy. Evidence available on diagnosis and management is scarce. They are fre...

journal_title：Expert review of anticancer therapy

authors： Clauser P,Marino MA,Baltzer PA,Bazzocchi M,Zuiani C

更新日期：2016-01-01 00:00:00

abstract：:Many solid tumors, including breast and prostate cancer, metastasize to bone, thereby putting patients at high risk for developing skeletal complications including pathologic fracture, spinal cord compression and debilitating bone pain. Patients often live for many years after developing bone metastasis, a fact that h...

journal_title：Expert review of anticancer therapy

authors： Gulley J,Dahut WL

更新日期：2005-04-01 00:00:00

abstract：:Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) represents a distinct disease entity whose molecular phenotype predicts exquisite sensitivity to the reversible EGFR-tyrosine kinase inhibitors (TKIs) gefitinib or erlotinib. However, primary or acquired resistance to these agents remain...

journal_title：Expert review of anticancer therapy

authors： Metro G,Crinò L

更新日期：2011-05-01 00:00:00

abstract：:Proteasome inhibition has been shown to be an effective strategy for the treatment of multiple myeloma, as demonstrated by the clinical activity of the first-in-class agent bortezomib. Recently, the second-generation proteasome inhibitor carfilzomib has been approved in the USA in the relapsed and refractory setting, ...

journal_title：Expert review of anticancer therapy

authors： McBride A,Ryan PY

更新日期：2013-03-01 00:00:00

abstract：:Introduction: Prodrugs have been used to improve the selectivity and efficacy of cancer therapy by targeting unique abnormal markers that are overexpressed by cancer cells and are absent in normal tissues. In this context, different strategies have been exploited and new ones are being developed each year. Areas cover...

journal_title：Expert review of anticancer therapy

authors： Souza C,Pellosi DS,Tedesco AC

更新日期：2019-06-01 00:00:00

abstract：INTRODUCTION:About 50% of all patients with advanced testicular cancer demonstrate residual retroperitoneal or extraretroperitoneal masses. About two thirds of the masses harbour necrosis/fibrosis only whereas as about 10% and 40% harbour vital cancer or teratoma. Appropriate therapy will result in a high cure rate if ...

journal_title：Expert review of anticancer therapy

authors： Heidenreich A,Paffenholz P,Nestler T,Pfister D

更新日期：2019-04-01 00:00:00

abstract：:Before the advent of rationally designed targeted antineoplastic therapies, cladribine was identified as a lymphocyte-specific cytotoxic agent. Cladribine is a purine nucleoside analogue that is resistant to cellular catabolism. Through diverse mechanisms, cladribine is equally toxic to dividing and nondividing cells,...

journal_title：Expert review of anticancer therapy

authors： Sigal DS,Saven A

更新日期：2008-04-01 00:00:00

abstract：:A number of cancers occur with increased frequency in individuals with HIV infection. There is a debate as to whether or not hepatocellular cancer is one of these tumors. This article reviews the current data regarding incidence etiology, treatment and outcome for HIV-related hepatocellular cancer. It also attempts to...

journal_title：Expert review of anticancer therapy

authors： Powles T,Macdonald D,Nelson M,Stebbing J

更新日期：2006-11-01 00:00:00

abstract：:Malignant pleural mesothelioma is an aggressive fatal malignancy with a prognosis that has not significantly improved in the last decades. This review summarizes the current state of treatment and the various attempts that are made to improve overall survival for patients with malignant pleural mesothelioma. It also d...

journal_title：Expert review of anticancer therapy

authors： Schunselaar LM,Quispel-Janssen JM,Neefjes JJ,Baas P

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:The term 'morphomics' stands for the markers of body composition in muscle and adipose tissues. in recent years, as part of clinical cancer research, several associations between morphomics and outcome or toxicity were found in different treatment settings leading to a growing interest. we aim to review st...

journal_title：Expert review of anticancer therapy

authors： Bayar MA,Antoun S,Lanoy E

更新日期：2017-04-01 00:00:00

abstract：:Bladder cancer is the most frequently occurring tumor of the urinary system, with over 10,000 new diagnoses each year in the UK. Approximately 70% of these are non-muscle-invasive and limited to the mucosa (Ta) or submucosa (T1). These tumors are generally managed with transurethral resection followed by adjuvant intr...

journal_title：Expert review of anticancer therapy

authors： Cheung G,Dasgupta P,Guru KA,Billia M,Khan MS

更新日期：2012-06-01 00:00:00

abstract：:Rapid malignant proliferation, prior to effective tumor neoangiogenesis, creates a microenvironment around solid cancers, which is predominantly hypoxic and characterized by a high interstitial fluid pressure. Presumably as an adaptive response, tumor cells favor metabolic activity with apparently inefficient energy o...

journal_title：Expert review of anticancer therapy

authors： Abaza M,Luqmani YA

更新日期：2013-10-01 00:00:00

abstract：:In the new era of 'precision' cancer medicine, new drug development has shifted from cytotoxic chemotherapy to molecularly targeted agents. Eribulin mesylate, a microtubule-destabilizing agent, is the only 'classical' cytotoxic agent approved for the treatment of breast cancer in the last 7 years. This synthetic analo...

journal_title：Expert review of anticancer therapy

authors： Polastro L,Aftimos PG,Awada A

更新日期：2014-06-01 00:00:00

abstract：:The incidence of thyroid cancer is increasing by 4% per year. Thyroid cancer has become the eighth most common malignancy diagnosed in women. Papillary cancer accounts for 80% of all thyroid cancer. The management of papillary thyroid cancer is challenging, primarily because there have been no prospective randomized t...

journal_title：Expert review of anticancer therapy

authors： Rosenbaum MA,McHenry CR

更新日期：2009-03-01 00:00:00

abstract：:For most sporadic cancers, genetic susceptibility results from the additive effect of multiple genetic variants, each of which contributes a modest risk individually. The study of genetic single nucleotide polymorphisms (SNPs) may help explain the differences in individual cancer susceptibility and may assist in ident...

journal_title：Expert review of anticancer therapy

authors： Meyer LA,Westin SN,Lu KH,Milam MR

更新日期：2008-07-01 00:00:00

abstract：:Management of patients with chronic myeloid leukemia has become increasingly difficult over the last few years since there are a variety of treatment options available. The ultimate challenge is to decide the most appropriate treatment strategy for an individual patient. To facilitate this, assessment of an individual...

journal_title：Expert review of anticancer therapy

authors： Burton C,Marin D,Apperley J

更新日期：2005-04-01 00:00:00

abstract：:Alemtuzumab (Campath, MabCampath) is a humanized therapeutic monoclonal antibody (mAb) that recognizes the CD52 antigen expressed on normal and neoplastic lymphoid cells. This mAb is active in previously treated patients with B-cell chronic lymphocytic leukemia (B-CLL) refractory to alkylating agents and purine nucleo...

journal_title：Expert review of anticancer therapy

authors： Robak T

更新日期：2008-07-01 00:00:00

abstract：:Introduction: Management of clinically negative neck (cN0) in patients with parotid gland cancer is controversial. Treatment options can include observation, elective neck dissection or elective radiotherapy. Areas covered: We addressed the treatment options for cN0 patients with parotid gland cancer. A literature rev...

journal_title：Expert review of anticancer therapy

authors： Vartanian JG,Gonçalves Filho J,Kowalski LP,Shah JP,Suárez C,Rinaldo A,De Bree R,Rodrigo JP,Hamoir M,Takes RP,Mäkitie AA,Zbären P,Andreasen S,Poorten VV,Sanabria A,Hellquist H,Robbins KT,Bödeker CC,Silver C,Ferlito A

更新日期：2019-10-01 00:00:00

abstract：:Introduction: Small-cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumour, and its outcome is strongly conditioned by the rapid onset of resistance to conventional chemotherapeutics. First-line treatment with a combination of platinum agents and topoisomerase inhibitors has been the standard of care for...

journal_title：Expert review of anticancer therapy

authors： Van Den Borg R,Leonetti A,Tiseo M,Giovannetti E,Peters GJ

更新日期：2019-06-01 00:00:00